ArticleDiscover oncology2025
Role of the TGF-β/Smad3 pathway in pancreatic cancer cell growth and stem cell characteristics.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Translational insights and clinical challenges of targeting cancer stem cells.Signal transduction and targeted therapy · 2026Review
- Integrative multi-omics analysis identifies a core ferroptosis signature and validates resveratrol as a novel inducer in pancreatic cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Mechanisms of immunotherapy in cutaneous squamous cell carcinoma in the tumor microenvironment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is a highly malignant digestive system tumor with poor prognosis, and cancer stem cell (CSC) is known to drive its progression, metastasis, and recurrence. The transforming growth factor-β (TGF-β)/small mothers against decapentaplegic 3 (Smad3) signaling is implicated in various cancers, yet its role in PC remains underexplored. This study aimed to investigate the involvement of the TGF-β/Smad3 pathway in PC development and stem cell-like properties by examining its regulatory effects on PC cells. Publicly available bioinformatics platforms (GEPIA and XIANTAO) were used to analyze the differential expression of TGF-β and Smad3 in PC tissues and their correlation with patient prognosis. In vitro, the human PC cell line PANC-1 was used as a model system. TGF-β interference fragments and Smad3 overexpression plasmids were introduced into the cells via liposome-mediated transfection. The effects of the TGF-β/Smad3 pathway on PC cell proliferation, migration, and apoptosis were assessed using MTT, wound healing assays, flow cytometry, and western blot analysis. Additionally, the sphere formation assay was conducted to evaluate the influence of this pathway on CSC properties in PC. Bioinformatics analysis revealed that TGF-β and Smad3 were significantly upregulated in PC tissues compared to normal pancreatic tissues, with higher expression levels correlating with worse prognosis (P < 0.05). In vitro, inhibition of TGF-β reduced the expression of TGF-β and Smad3, decreased cell proliferation and migration, enhanced apoptosis, and suppressed sphere formation (P < 0.05). Conversely, Smad3 overexpression exhibited the opposite effects, promoting PC cell growth and enhancing stem cell characteristics (P < 0.05). The TGF-β/Smad3 signaling pathway was activated in PC and played a crucial role in promoting tumor growth, migration, and CSC-like traits. Targeting this pathway may offer therapeutic potential for improving PC prognosis and treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.